AU4542893A - Methods and compositions for treating depression and other disorders using optically pure (-) sibutramine - Google Patents

Methods and compositions for treating depression and other disorders using optically pure (-) sibutramine

Info

Publication number
AU4542893A
AU4542893A AU45428/93A AU4542893A AU4542893A AU 4542893 A AU4542893 A AU 4542893A AU 45428/93 A AU45428/93 A AU 45428/93A AU 4542893 A AU4542893 A AU 4542893A AU 4542893 A AU4542893 A AU 4542893A
Authority
AU
Australia
Prior art keywords
sibutramine
amount
pharmaceutically acceptable
human
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU45428/93A
Other languages
English (en)
Inventor
James W. Young
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sunovion Pharmaceuticals Inc
Original Assignee
Sepracor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sepracor Inc filed Critical Sepracor Inc
Publication of AU4542893A publication Critical patent/AU4542893A/en
Priority to AU45298/97A priority Critical patent/AU721924B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU45428/93A 1992-06-23 1993-06-22 Methods and compositions for treating depression and other disorders using optically pure (-) sibutramine Abandoned AU4542893A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU45298/97A AU721924B2 (en) 1992-06-23 1997-11-21 Methods and compositions for treating depression and other disorders using optically pure (-) sibutramine

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US90304092A 1992-06-23 1992-06-23
US903040 1992-06-23
PCT/US1993/005966 WO1994000114A1 (fr) 1992-06-23 1993-06-22 Procedes et compositions utilises pour traiter la depression et d'autres affections avec de la sibutramine (-) optiquement pure

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU45298/97A Division AU721924B2 (en) 1992-06-23 1997-11-21 Methods and compositions for treating depression and other disorders using optically pure (-) sibutramine

Publications (1)

Publication Number Publication Date
AU4542893A true AU4542893A (en) 1994-01-24

Family

ID=25416838

Family Applications (1)

Application Number Title Priority Date Filing Date
AU45428/93A Abandoned AU4542893A (en) 1992-06-23 1993-06-22 Methods and compositions for treating depression and other disorders using optically pure (-) sibutramine

Country Status (5)

Country Link
EP (1) EP0647134A4 (fr)
JP (1) JPH08500093A (fr)
AU (1) AU4542893A (fr)
CA (1) CA2138998A1 (fr)
WO (1) WO1994000114A1 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020006963A1 (en) * 1992-06-23 2002-01-17 Young James W. Method of using and compositions comprising (-) sibutramine optionally in combination with other pharmacologically active compounds
GB9402641D0 (en) * 1994-02-11 1994-04-06 Boots Co Plc Therapeutic agents
US5676967A (en) * 1995-04-18 1997-10-14 Brennen Medical, Inc. Mesh matrix wound dressing
DE19518988A1 (de) * 1995-05-29 1996-12-05 Basf Ag Verwendung arylsubstituierter Cyclobutylalkylamine zur Behandlung der Fettleibigkeit
GB9619962D0 (en) * 1996-09-25 1996-11-13 Knoll Ag Medical treatment
US6476078B2 (en) 1999-08-11 2002-11-05 Sepracor, Inc. Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
US6974838B2 (en) 1998-08-24 2005-12-13 Sepracor Inc. Methods of treating or preventing pain using sibutramine metabolites
US6331571B1 (en) 1998-08-24 2001-12-18 Sepracor, Inc. Methods of treating and preventing attention deficit disorders
US6339106B1 (en) 1999-08-11 2002-01-15 Sepracor, Inc. Methods and compositions for the treatment and prevention of sexual dysfunction
US6046242A (en) * 1998-11-27 2000-04-04 Basf Aktiengesellschaft Use of aryl-substituted cyclobutylalkylamines for treating urinary incontinence
US6342533B1 (en) 1998-12-01 2002-01-29 Sepracor, Inc. Derivatives of (−)-venlafaxine and methods of preparing and using the same
US6197828B1 (en) 1998-12-01 2001-03-06 Sepracor, Inc. Derivatives of (+)-venlafaxine and methods of preparing and using the same
US6696495B2 (en) 1998-12-02 2004-02-24 Snowden Pharmaceuticals, Llc Treatment of disorders secondary to organic impairments
US6323242B1 (en) 1998-12-02 2001-11-27 Peter Sterling Mueller Treatment of disorders secondary to organic impairments
TR200102699T2 (tr) * 1999-03-19 2002-03-21 Knoll Gmbh Kronik mafsal bozukluĞunun (osteoarthritis) tedavisi
PL350924A1 (en) 1999-04-06 2003-02-10 Sepracor Inc Derivatives of venlafaxine and methods of preparing and using the same
US6399826B1 (en) 1999-08-11 2002-06-04 Sepracor Inc. Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
US20020115727A1 (en) * 2000-12-04 2002-08-22 Senanayake Chris H. Synthesis, methods of using, and compositions of hydroxylated cyclobutylalkylamines
ES2290281T5 (es) 2001-02-12 2017-09-11 Wyeth Llc Sal de succinato de O-desmetil-venlafaxina
WO2002083631A1 (fr) 2001-04-13 2002-10-24 Sepracor Inc. Procedes permettant la preparation de didesmethylsibutramine et d'autres derives de sibutramine
US6602911B2 (en) 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
JP2005523334A (ja) * 2002-04-24 2005-08-04 サイプレス バイオサイエンス， インコーポレイテッド ストレス関連障害を含む機能的身体障害の予防および処置
CN1671368A (zh) * 2002-07-24 2005-09-21 柏树生物科学公司 疼痛继发性抑郁（dsp）的治疗

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3008993A1 (de) * 1980-03-08 1981-10-01 Röhm Pharma GmbH, 6100 Darmstadt Pharmazeutische zubereitungen
IE52768B1 (en) * 1981-04-06 1988-02-17 Boots Co Ltd 1-arylcyclobutylalkylamine compounds useful as therapeutic agents
ZA821577B (en) * 1981-04-06 1983-03-30 Boots Co Plc Therapeutic agents
GB8531071D0 (en) * 1985-12-17 1986-01-29 Boots Co Plc Therapeutic compound
JP2675573B2 (ja) * 1988-03-31 1997-11-12 科研製薬株式会社 脳機能改善剤
IE61928B1 (en) * 1988-11-29 1994-11-30 Boots Co Plc Treatment of obesity
US5104899A (en) * 1990-08-13 1992-04-14 Sepracor, Inc. Methods and compositions for treating depression using optically pure fluoxetine

Also Published As

Publication number Publication date
JPH08500093A (ja) 1996-01-09
CA2138998A1 (fr) 1994-01-06
WO1994000114A1 (fr) 1994-01-06
EP0647134A1 (fr) 1995-04-12
EP0647134A4 (fr) 1997-07-30

Similar Documents

Publication Publication Date Title
AU4542893A (en) Methods and compositions for treating depression and other disorders using optically pure (-) sibutramine
US6110973A (en) Methods for treating obesity and weight gain using optically pure (-)-bupropion
AU4542993A (en) Methods and compositions for treating depression and other disorders using optically pure (+) sibutramine
US5648396A (en) Methods for treating depression and other disorders using optically pure R (-) fluoxetine and monoamine oxidase inhibitor
RU2001614C1 (ru) R (+)-N-Пропаргил-1-аминоиндан и его фармацевтически пригодные кислотно-аддитивные соли и фармацевтическа композици , обладающа ингибирующей B-форму фермента моноаминооксидазы активностью
TWI298255B (en) Use of optically pure (s.s)-reboxetine in the manufacture of a medicament for the treatment or prevention of fibromyalgia or another somatoform disorder
US20020006964A1 (en) Methods of using and compositions comprising (+) sibutramine optionally in combination with other pharmacologically active compounds
JP2003501344A (ja) （＋）−ベンラファキシン誘導体並びにその製造方法および使用方法
JP2013256526A (ja) （−）−ベンラファキシン誘導体並びにその製造方法および使用方法
EP1904066B1 (fr) COMBINAISONS D'ESZOPICLONE ET DE TRANS 4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDRO-N-METHYL-1-NAPHTALENAMINE OR TRANS 4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDRO-1-NAPHTALENAMINE, pour le TRAITEMENT DE LA MENOPAUSE, perimenopause ET des TROUBLES COGNITIFS
EP0687472A2 (fr) Potentialisation d'un médicament par un antagoniste du récepteur sérotonine 1A
CZ20013607A3 (cs) Farmaceutický prostředek
DE69607904T2 (de) Potenzierung von Serotonin-Wirkstoffresponz
US4690949A (en) Therapeutic drug for dementia
CA2318960A1 (fr) Utilisations pharmaceutiques de (+)-bupropion optiquement pur
JP2004501130A (ja) ５−ｈｔ３受容体及び神経細胞のニコチン性受容体に対するアンタゴニストとしての１−アミノ−アルキルシクロヘキサン
WO2002060428A2 (fr) Modes d'utilisation et compositions comprenant de la (-) sibutramine, eventuellement combinee a d'autres composes pharmaceutiquement actifs
AU721924B2 (en) Methods and compositions for treating depression and other disorders using optically pure (-) sibutramine
US5492933A (en) Methods and compositions for treating urinary incontinence and other disorders using optically pure R-terodiline and hydroxylated derivatives thereof
WO1992013452A1 (fr) Procedes d'utilisation et compositions de r(-) fluoxetine
US4141993A (en) Compounds of diphenylcyclopentylamine type and methods for their preparation
WO1995010270A1 (fr) Procedes de traitement de l'incontinence urinaire a l'aide de terodiline optiquement pure